EUVIMEDEUVIMED entdecken
Crossref

GLP-1 Agonists for Obesity—A New Recipe for Success?

Dariush Mozaffarian

JAMA · 26.03.2024 · 331 (12) · 1007

DOI: 10.1001/jama.2024.2252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 26.03.2024. Verfasst von Dariush Mozaffarian. Beteiligte Einrichtung: Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Viewpoint discusses the drawbacks of using glucagon-like peptide 1 (GLP-1) agonists to treat obesity and presents an alternative approach of initial, staged GLP-1 agonist treatment supported by long-term lifestyle programming, including medically appropriate groceries or meals (“Food Is Medicine”), to address the cost, health, and equity burdens of obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1ObesityAnti-Obesity AgentsHumansDiabetes Mellitus, Type 2Hypoglycemic Agents

Substanzen

Glucagon-Like Peptide 1Hypoglycemic AgentsAnti-Obesity Agents

Autor:innen und Institutionen

  • Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts.
  • Division of Cardiology, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts.

Zitieren

APA

Mozaffarian, D. (2024). GLP-1 Agonists for Obesity—A New Recipe for Success?. JAMA, 331(12), 1007. https://doi.org/10.1001/jama.2024.2252

Vancouver

Mozaffarian D. GLP-1 Agonists for Obesity—A New Recipe for Success?. JAMA. 2024;331(12):1007. doi:10.1001/jama.2024.2252

BibTeX
@article{Mozaffarian2024,
  author = {Mozaffarian, Dariush},
  title = {GLP-1 Agonists for Obesity—A New Recipe for Success?},
  journal = {JAMA},
  year = {2024},
  volume = {331},
  number = {12},
  pages = {1007},
  doi = {10.1001/jama.2024.2252}
}
Kostenlos starten →